(Hypertension. 1999;34:773-778.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation (S.T.T.), Rochester, Minn; the University of Texas-Houston Health Science Center (E.B.), Houston, Tex; and the Department of Human Genetics, University of Michigan (C.F.S.), Ann Arbor.
Correspondence to Stephen T. Turner, MD, Division of Hypertension, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail turner.stephen{at}mayo.edu
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure hypertension, genetic angiotensin-converting enzyme polymorphism
| Introduction |
|---|
|
|
|---|
Association studies with biallelic markers can also be helpful in indicating whether variation in a candidate gene may influence blood pressure. Most association studies that involved the ACE gene have relied on an insertion/deletion (I/D) polymorphism in intron 16, with the D allele associated with an increase in plasma ACE activity in a codominant fashion.4 Several previous studies reported associations between interindividual variation in blood pressure level5 6 or the probability of having hypertension7 8 9 and the I/D polymorphism. In the recent study of O'Donnell and colleagues,1 increased diastolic blood pressure and increased odds of having hypertension were associated with the D allele in men but not women. Although numerous other studies reported no association between measures of blood pressure and the I/D polymorphism,10 11 12 13 only one of these latter studies considered women and men separately.11
Despite universal recognition that blood pressure is influenced by interactions between the effects of many genetic and environmental factors, the possibility of detecting statistically significant interactions between genetic effects measured by the ACE I/D polymorphism and effects of other genetic and environmental factors has received little attention. Because such interactions may give rise to different relationships between genotypic variation and phenotypic variation in different environments,14 15 some previous studies may have falsely concluded that interindividual variation in blood pressure is not associated with the I/D polymorphism because the context dependency of the association was not considered.
The objective of the present study was to assess whether the influences of gender, age, or measures of body size on blood pressure are homogeneous among genotypes of the ACE I/D polymorphism. We studied a sample of non-Hispanic white individuals from the same 3-generation pedigrees that provided the young male sibling pairs in which Fornage and colleagues2 reported evidence of linkage between the hGH microsatellite marker and a gene that influenced diastolic blood pressure. We found evidence that the associations between measures of blood pressure and variation in genotypes of I/D polymorphism were not only dependent on gender but also on age and measures of body size.
| Methods |
|---|
|
|
|---|
Sampled individuals of each gender were stratified into 3 age groups: 5 to 29.9 years; 30 to 49.9 years; and 50 to 90 years, which corresponded to the age ranges of children, parents, and grandparents. Among subjects <50 years of age, systolic and diastolic blood pressure levels were analyzed as continuously-distributed, quantitative traits because individuals with factors that alter blood pressure were excluded (see exclusion criteria above). Among subjects 50 to 90 years of age, blood pressure diagnostic category (hypertension versus normotension) was considered a discrete trait because individuals treated with antihypertensive medications were included.
Study Protocol
The study protocol was approved by the Institutional Review
Board of the Mayo Clinic and all procedures were followed in accordance
with institutional guidelines. Each participant signed a consent form;
afterward, a physician reviewed the participant's medical history and
performed a brief physical examination including measurement of height,
weight, and blood pressure as previously described.16
Three blood pressure readings,
2 minutes apart, were obtained in the
right arm after the participant sat quietly for
5 minutes. Averages
of the 3 readings were used in the analyses.
Blood Pressure Diagnostic Categories
Each participant was assigned to 1 of the blood pressure
diagnostic categories defined by the following
criteria.
Normotension
These individuals had never been treated with medication for
hypertension, and their systolic and diastolic
blood pressures were <140 and <90 mm Hg, respectively, at the
clinic visit. None of these individuals had concomitant illnesses or
were being treated with medications known to lower blood
pressure.
Hypertension
These individuals reported a previous diagnosis of hypertension
and were being treated with antihypertensive medications or their
systolic blood pressure was
140 mm Hg or their
diastolic blood pressure was
90 mm Hg at the
study visit.
Laboratory Methods
Blood samples drawn before blood pressure measurement were
anticoagulated with EDTA, and buffy coat was separated and stored at
-80°C. Genomic DNA was extracted from thawed buffy coat by a
salting-out procedure. Aliquots of 100 ng of genomic DNA were
transferred to 96-well plates (Costar) for amplification of the I/D
polymorphism of the ACE gene by polymerase chain reaction as
described by Rigat and colleagues.4 Polymerase chain
reaction products were electrophoresed on 2% agarose gels; the
190-bp deletion allele and the 490-bp insertion allele were
identified by ethidium bromide staining.
Statistical Methods
For quantitative traits, means and standard deviations were
calculated for each ACE genotype within each age and gender
group; a 1-way ANOVA was used to assess differences in means among
genotypes within the age and gender groups. Relative
frequencies of ACE genotypes and alleles were calculated
for each age and gender group; in subjects 50 to 90 years of age,
relative frequencies of blood pressure diagnostic
categories were calculated for each gender and genotype group.
A
2 contingency test was used to assess
differences in relative frequencies between genders within each age
group and among age groups and genotype groups within each
gender.
In age and gender groups in which the subjects were <50 years of age,
we used linear regression models to assess whether variation in ACE
genotype made a statistically significant contribution to the
prediction of systolic or diastolic blood pressure
level. In groups in which the subjects were 50 to 90 years of age, we
used logistic regression models to assess whether variation in ACE
genotype made a statistically significant contribution to
prediction of blood pressure diagnostic category. With each
type of regression model, we first estimated the influence of variation
among ACE genotypes on variation in measures of blood pressure
level (or probability of having hypertension) and ignored variation in
age, height, and weight. Second, we estimated the influence of
variation among ACE genotypes on variation in measures of blood
pressure level (or probability of having hypertension) after adjustment
for variation in age, height, and weight. Third, to assess
heterogeneity among genotypes in the regression
of blood pressure level or diagnostic category on each
concomitant trait, we included in the regression model the interaction
of ACE genotype with the concomitant being considered. Results
were considered statistically significant when an observed test
statistic was expected
5% of the time if the null hypothesis were
true.
| Results |
|---|
|
|
|---|
|
Concomitant Traits
Means and variances for age, height, and weight did not differ
significantly among ACE genotypes except in 2 of the age and
gender groups (Table 2). In female
subjects 50 to 90 years of age, mean weight and its variance differed
significantly among genotypes (P=0.030 for the
contrast of means, and P=0.011 for the contrast of
variances); and in female subjects 30 to 49.9 years of age, the
variance of weight differed significantly among genotypes
(P=0.044).
|
Associations of Blood Pressure with ACE Genotype
In age and gender groups with subjects <50 years of age, means
for systolic and diastolic blood pressure did not
differ significantly among ACE genotypes (Table 3). Variation in ACE genotype
also did not make a statistically significant contribution to
prediction of blood pressure level after adjustment by linear
regression for variation in age, height, and weight. In these latter
models (not shown), the percentage of interindividual variation in
adjusted systolic or diastolic blood pressure level
(R2x100%) explained by variation in
ACE genotype was <2%. In contrast, the percentage of
interindividual variation in systolic blood pressure level
explained by the combined effects of variation in age, height, and
weight ranged from 6.7% (males 30 to 49.9 years, P=0.003)
to 34.3% (males 5 to 29.9 years, P<0.001), and the
percentage of interindividual variation in diastolic blood
pressure level explained ranged from 2.0% (females 5 to 29.9 years,
P=0.03) to 6.6% (females 30 to 49.9 years,
P<0.001).
|
In females and males 50 to 90 years of age, relative frequencies of the blood pressure diagnostic categories did not differ significantly among genotypes (Table 4). Consistent with this observation, ACE genotype did not make a statistically significant contribution to the prediction of blood pressure diagnostic category in females or males when it was the only predictor included in logistic regression models (not shown). This was also true when ACE genotype was entered into the logistic regression model after entering age, height, and weight. In contrast, in these latter models, the combined effects of variation in age, height, and weight made statistically significant contributions to predicting blood pressure diagnostic category in each gender (P<0.001).
|
Heterogeneity of Regression
Relationships
We conducted additional analyses to assess whether the
regression relationships of blood pressure level or
diagnostic category with age, height, or weight differed
significantly among ACE genotypes (Table 5 and Figures 1 and 2).
These analyses addressed whether genetic effects on blood
pressure measured by the I/D polymorphism might be dependent on
levels of the concomitant traits. (In contrast, the analyses
presented in Tables 3 and 4 assumed that these effects
were independent of variation in age and measures of body size.) In
female subjects 5 to 29.9 years old, we found that the regressions of
systolic blood pressure level on age and on weight and of
diastolic blood pressure level on age were significantly
heterogenous among genotypes (Figure 1
and Table 5). In each instance, the slope of the regression
relationship (Figure 1) and the percentage of interindividual
variation in blood pressure explained by the regression relationship
(Table 5) was greater in I/D heterozygotes than in II or DD
homozygotes. Moreover, the rank order of expected blood pressure level
reversed from low values of the concomitant trait, in which blood
pressure level was lower for I/D heterozygotes than for II or DD
homozygotes, to high values of the concomitant trait, in which blood
pressure level was higher for I/D heterozygotes than for II or DD
homozygotes (Figure 1). In male subjects 5 to 29.9 years old and
in both females and males 30 to 49.9 years old, there was no evidence
of statistically significant heterogeneity in the
linear regression relationships of systolic or
diastolic blood pressure level with age, height, or weight
(not shown).
|
|
|
In males 50 years of age or older, we found that the logistic regression of the probability of having hypertension on height was significantly heterogenous among genotypes (Figure 2). The relationship between the probability of having hypertension and height was inverse and significantly different from zero in II homozygotes (P<0.001) but was not significantly different from zero in I/D heterozygotes (P=0.243) or in DD homozygotes (P=0.562).
| Discussion |
|---|
|
|
|---|
First, the regulation of blood pressure level through interactions of multiple biochemical, physiological, and anatomical traits with redundant, counterbalancing vasopressor and depressor actions17 makes it unlikely that variation in any single etiologic factor (genetic or environmental) will have a large effect on interindividual differences in blood pressure. Moreover, a considerable body of evidence from studies in experimental animals and plants indicates that the relationship between phenotype and genotype is usually not constant over a broad range of environments. Each genotype may have a different "norm of reaction" that determines the distribution of possible phenotypes associated with a distribution of environments.14 15 The regression lines in Figures 1 and 2 indicate different norms of reaction for the expected blood pressure phenotype associated with each ACE genotype over the observed range of age or measures of body size. In this sample, not only the magnitude but also the direction of blood pressure differences among ACE genotypes changed across the range of environments indexed by measures of age, height, and weight. The greater slope and range of expected blood pressure levels in I/D heterozygotes than in II or DD homozygotes (Figure 1) suggests that the latter are more "homeostatic" than I/D heterozygotes. These figures illustrate how differences between ACE genotypes may be apparent in particular environments, but, when effects are averaged over all environments, the I/D polymorphism appears not to influence blood pressure level or diagnostic category (Figures 1 and 2).
To the best of our knowledge, the few previous studies that have investigated have found evidence of interactions between effects measured by the ACE I/D polymorphism and other measures of genetic and environmental variation. In one study, the DD genotype was associated with higher blood pressure levels only in a subset of untreated hypertensive patients who did not have additional risk factors for cardiovascular disease (smoking, hypercholesterolemia, or diabetes).18 The authors proposed that such context dependencies may in part account for inconsistencies in the effects attributed to the ACE polymorphism among studies that have sampled geographically, racially, and medically diverse populations. In a sample from the Framingham Heart Study, the DD genotype was a significant predictor of increased odds of having hypertension only in individuals who were also homozygous for a hypertension-associated allele at the angiotensinogen locus.19 Finally, in a sample of untreated hypertensive patients, systolic and diastolic blood pressure levels were influenced by interaction between effects associated with the ACE I/D polymorphism and a polymorphism of the angiotensin II receptor type 1.5
Because overlap of the sample with our previous linkage study2 was limited to the 5- to 29.9-year-old male and female subjects in the present study, it is appropriate to ask why we found no evidence of association between the ACE I/D polymorphism and blood pressure levels in 5- to 29.9-year-old male subjects in this study, although our previous linkage study was positive only in young male siblings. One possible explanation is that the ACE I/D polymorphism, which itself may have no effect on blood pressure, is in linkage equilibrium with functional variants elsewhere in the ACE gene that are responsible for the blood pressure effects detected in the previous linkage study.20 Moreover, the previous linkage study used a highly polymorphic microsatellite marker in the regulatory region of the hGH gene and cannot exclude the possibility that variation in another closely-linked gene, instead of ACE, was responsible for the positive linkage result.2 In addition, for the previous linkage analyses, blood pressure levels were "adjusted" in each gender to remove variation attributable to differences in age and measures of body size ignoring genotypic classification. Thus, the possibility was not considered that the relationship between interindividual variation in blood pressure and variation in the ACE gene may be dependent on age or measures of body size, such as what we found in the young female subjects in the present study.
With the mapping and sequencing of all human genes soon to be completed,21 considerable efforts are underway to identify and characterize the subset that influence blood pressure and its cardiovascular disease complications. Although the ACE gene has been one of the most widely and intensively studied candidate genes, a simple yes or no answer to the question of whether variation in the ACE gene influences blood pressure is not possible.22 On the basis of findings in this and other studies, we believe that the ACE gene is likely to be one of many genes whose variation has small effects on blood pressure in some contexts but not in others. For such genes, the more appropriate question may be what are the contexts in which variation in the gene does and does not influence blood pressure? Such an approach emphasizes the need to study not only variants of the genes that are candidates to influence blood pressure but also the genetic and environmental backgrounds in which they are expressed to unravel the complex causes of hypertension.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received May 8, 1999; first decision July 1, 1999; accepted July 26, 1999.
| References |
|---|
|
|
|---|
2.
Fornage M, Amos C, Kardia S, Sing C, Turner S,
Boerwinkle E. Variation in the region of the
angiotensin-converting enzyme gene influences
interindividual differences in blood pressure levels in young white
males. Circulation. 1998;97:17731779.
3. Jeunemaitre X, Lifton R, Hunt S, Williams R, Lalouel J. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet. 1992;1:7275.[Medline] [Order article via Infotrieve]
4. Rigat B, Hubert C, Alhenc-Gelas F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:13431346.
5. Hingorani A, Jia H, Stevens P, Hopper R, Claire Dickerson J, Brown M. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens. 1995;13:16021609.[Medline] [Order article via Infotrieve]
6. Barley J, Blackwood A, Miller M, Markandu N, Jeffery S, Cappuccio F, MacGregor G, Sagnella G. Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin-angiotensin system in Caucasian and Afro-Caribbean peoples. J Hum Hypertens. 1996;10:3135.[Medline] [Order article via Infotrieve]
7. Zee R, Lou Y, Griffiths L, Morris B. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun. 1992;184:915.[Medline] [Order article via Infotrieve]
8. Morise T, Takeuchi Y, Takeda R. Angiotensin-converting enzyme polymorphism and essential hypertension. Lancet. 1994;343:125.
9. Duru K, Farrow S, Wang J, Lockette W, Kurtz T. Frequency of a deletion polymorphism in the gene for angiotensin converting enzyme is increased in African-Americans with hypertension. Am J Hypertens. 1994;7:759762.[Medline] [Order article via Infotrieve]
10. Chiang F, Lai Z, Chern T, Tseng C, Hsu K, Lo H, Tseng Y. Lack of association of the angiotensin converting enzyme gene polymorphism with essential hypertension in a Chinese population. Am J Hypertens. 1997;10:197201.[Medline] [Order article via Infotrieve]
11.
Kiema T, Kauma H, Rantala A, Lilja M, Reunanen A,
Kesaniemi Y, Savolainen M. Variation at the
angiotensin-converting enzyme gene and
angiotensinogen gene loci in relation to blood pressure.
Hypertension. 1996;28:10701075.
12.
Harrap S, Davidson H, Cornor J, Soubrier F, Corvol P,
Fraser R, Foy C, Watt G. The angiotensin I converting
enzyme gene and predisposition to high blood pressure.
Hypertension. 1993;21:455460.
13. Schmidt S, van Hooft I, Grobbee D, Ganten D, Ritz E. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch hypertension and offspring study. J Hypertens. 1993;11:345348.[Medline] [Order article via Infotrieve]
14. Suzuki D, Griffiths A, Miller J, Lewontin R. Quantitative Genetics. In: An Introduction to Genetic Analyses. New York, NY: W. H. Freeman & Co;. 1986: 514519.
15. Lewontin R. Genotype and phenotype. In: Fox Keller E, Lloyd E, eds. Keywords in Evolutionary Biology. Cambridge, Mass: Harvard University Press;1992: 137144.
16. Turner S, Rebbeck T, Sing C. Erythrocyte sodium transport and the probability of having hypertension. J Hypertens. 1996;14:829837.[Medline] [Order article via Infotrieve]
17. Guyton AC, Hall JE, Lohmeier TE, Jackson TE, Kastner PR. Blood pressure regulation: basic concepts. Fed Proc. 1981;40:22522256.[Medline] [Order article via Infotrieve]
18. Celetano A, Mancini F, Crivaro M, Palmieri V, De Stefano V, Ferrara L, Di Minno G, de Simone G. Influence of cardiovascular risk factors on relation between angiotensin converting enzyme-gene polymorphism and blood pressure in arterial hypertension. J Hypertens. 1998;16:985991.[Medline] [Order article via Infotrieve]
19. Borecki I, Province M, Ludwig E, Ellison R, Folsom A, Heiss G, Lalouel J, Higgins M, Rao D. Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI family heart study. Ann Epidemiol. 1997;7:1321.[Medline] [Order article via Infotrieve]
20. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 1996;58:12681278.[Medline] [Order article via Infotrieve]
21.
Collins F. Medical and societal consequences of the
human genome project. N Engl J Med. 1999;341:2837.
22.
Soubrier F. Blood pressure gene at the
angiotensin Iconverting enzyme locus: chronicle of a gene
foretold. Circulation. 1998;97:17631765.
This article has been cited by other articles:
![]() |
L. Lin, L. Finn, J. Zhang, T. Young, and E. Mignot Angiotensin-converting Enzyme, Sleep-disordered Breathing, and Hypertension Am. J. Respir. Crit. Care Med., December 15, 2004; 170(12): 1349 - 1353. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Dong, X. Wang, H. Zhu, F. A. Treiber, and H. Snieder Endothelin-1 Gene and Progression of Blood Pressure and Left Ventricular Mass: Longitudinal Findings in Youth Hypertension, December 1, 2004; 44(6): 884 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Chaves, D. Corella, J. V. Sorli, P. Marin-Garcia, M. Guillen, and J. Redon Polymorphisms of the Renin-Angiotensin System Influence Height in Normotensive Women in a Spanish Population J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2301 - 2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Kammerer, N. Gouin, P. B. Samollow, J. F. VandeBerg, J. E. Hixson, S. A. Cole, J. W. MacCluer, and L. D. Atwood Two Quantitative Trait Loci Affect ACE Activities in Mexican-Americans Hypertension, February 1, 2004; 43(2): 466 - 470. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Kammerer, D. L. Rainwater, J. L. Schneider, L. A. Cox, M. C. Mahaney, J. Rogers, and J. F. VandeBerg Two Loci Affect Angiotensin I-Converting Enzyme Activity in Baboons Hypertension, March 1, 2003; 41(3): 854 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.R. Abraham, L. J. Olson, M. J. Joyner, S. T. Turner, K. C. Beck, and B. D. Johnson Angiotensin-Converting Enzyme Genotype Modulates Pulmonary Function and Exercise Capacity in Treated Patients With Congestive Stable Heart Failure Circulation, October 1, 2002; 106(14): 1794 - 1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Tiago, N. J. Samani, G. P. Candy, R. Brooksbank, E. N. Libhaber, P. Sareli, A. J. Woodiwiss, and G. R. Norton Angiotensinogen Gene Promoter Region Variant Modifies Body Size-Ambulatory Blood Pressure Relations in Hypertension Circulation, September 17, 2002; 106(12): 1483 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Volzke, J. Engel, V. Kleine, C. Schwahn, J. B. Dahm, L. Eckel, and R. Rettig Angiotensin I-Converting Enzyme Insertion/Deletion Polymorphism and Cardiac Mortality and Morbidity After Coronary Artery Bypass Graft Surgery* Chest, July 1, 2002; 122(1): 31 - 36. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lussier-Cacan, A. Bolduc, M. Xhignesse, T. Niyonsenga, and C. F. Sing Impact of Alcohol Intake on Measures of Lipid Metabolism Depends on Context Defined by Gender, Body Mass Index, Cigarette Smoking, and Apolipoprotein E Genotype Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 824 - 831. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |